Pro: intravenous tissue plasminogen activator in stroke patients with rapid, complete recovery during evaluation (transient ischemic attack) and evidence of middle cerebral artery occlusion.
Köhrmann
Martin
M
Department of Neurology, University Hospital Erlangen, Erlangen, Germany. martin.koehrmann@uk-erlangen.de
Schellinger
Peter D
PD
D002545:Brain Ischemia / Q000139:chemically induced / Q000453:epidemiology; D003097:Collateral Circulation / Q000502:physiology; D018450:Disease Progression; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy*; D007275:Injections, Intravenous; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000503:physiopathology; D012306:Risk; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator